Manufactures and sells gastrointestinal and surgical endoscopes for medical diagnostics and procedures. Now — the numbers.
This is an established company with proven profits.
No real growth (4% a year).
The market pays 33.2× for every dollar this company earns in a year — a price that already assumes things go well.
No analyst target is on record for this company.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Trading Liquidity: The shares change hands too rarely for smooth trading.
The stock trades 46% below its peak. The market has trimmed its expectations for the company.
It pays out $0.19 per share each year — regular cash for whoever holds the stock.
The company’s market value is 33 times its annual profit. Even a small disappointment could hit the price hard.
Since the drop from its peak, buyer appetite hasn’t come back. Council score: 0/10.
Getting in and out without moving the price could prove difficult. Council score: 2/10.
We don’t have a report card for this stock yet — the data isn’t mature enough to grade. No grade is information too: it means the evidence is thin.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: the revenue breakdown.